Table 4.
Cytokine levels in the culture supernatant of ARPE-19 cells incubated with anti-VEGF antibody: comparison between dark and light irradiation.
| Anti-VEGF Antibody | Aflibercept | Ranibizumab | ||||
|---|---|---|---|---|---|---|
| Category | Dark | Light | p Value | Dark | Light | p Value |
| Level | Level | Dark vs. Light | Level | Level | Dark vs. Light | |
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |||
| PDGF-BB | 1.51 ± 0 | 2.02 ± 0 | 1.000 | 2.64 ± 2.31 | 1.01 ± 1.43 | 0.243 |
| IL-1β | 0.66 ± 0.11 | 0 | 0.007 | 0.70 ± 0.06 | 0 | 0.002 |
| IL-1ra | 12.2 ± 0.60 | 15.9 ± 1.15 | 0.028 | 11.7 ± 0 | 14.0 ± 2.04 | 0.126 |
| IL-2 | 0.39 ± 0.55 | 1.34 ± 0.17 | 0.073 | 0 | 0.90 ± 0.38 | 0.040 |
| IL-4 | 0 | 0 | — | 0 | 0 | — |
| IL-5 | 0 | 0 | — | 0 | 0 | — |
| IL-6 | 17.9 ± 1.20 | 4.16 ± 0.47 | 0.002 | 17.0 ± 1.31 | 3.53 ± 0.12 | 0.002 |
| IL-7 | 2.20 ± 0.15 | 0.74 ± 0 | 0.003 | 3.50 ± 0.28 | 1.66 ± 0.62 | 0.031 |
| IL-8 | 47.4 ± 6.80 | 24.9 ± 0.88 | 0.022 | 52.8 ± 1.99 | 26.1 ± 5.90 | 0.013 |
| IL-9 | 3.25 ± 0 | 1.66 ± 0.43 | 0.017 | 3.88 ± 0.70 | 0.71 ± 1.00 | 0.034 |
| IL-10 | 0 | 0 | — | 0 | 0 | — |
| IL-12 | 0 | 0 | — | 3.68 ± 0.30 | 0 | 0.002 |
| IL-13 | 0.41 ± 0 | 0.21 ± 0.29 | 0.211 | 0.54 ± 0.06 | 0.21 ± 0.29 | 0.128 |
| IL-15 | 5.51 ± 0.46 | 4.06 ± 0.45 | 0.043 | 5.22 ± 0.06 | 3.74 ± 0.18 | 0.004 |
| IL-17A | 10.3 ± 1.83 | 7.67 ± 0.31 | 0.094 | 10.9 ± 1.22 | 5.73 ± 1.53 | 0.032 |
| Eotaxin | 0 | 0 | — | 0 | 0 | — |
| bFGF | 301.3 ± 29.8 | 127.0 ± 22.5 | 0.011 | 319.3 ± 8.35 | 120.4 ± 29.3 | 0.006 |
| G-CSF | 0 | 0 | — | 0 | 0 | — |
| GM-CSF | 0 | 0 | — | 0 | 0 | — |
| IFN-γ | 0 | 0 | — | 0 | 0 | — |
| IP-10 | 0 | 0 | — | 0 | 0 | — |
| MCP-1 | 231.1 ± 11.8 | 55.6 ± 2.19 | 0.001 | 211.7 ± 11.0 | 57.7 ± 0.26 | 0.001 |
| MIP-1α | 0.13 ± 0.18 | 0.13 ± 0.18 | 0.550 | 0 | 0.34 ± 0.11 | 0.026 |
| MIP-1β | 0 | 0 | — | 0 | 0 | — |
| RANTES | 0 | 0 | — | 0 | 0 | — |
| TNFα | 0 | 0 | — | 0 | 0 | — |
| VEGF-A | 3.24 ± 0.28 | 3.15 ± 0.42 | 0.407 | 115.2 ± 3.04 | 47.4 ± 12.4 | 0.009 |
Concentrations of aflibercept and ranibizumab were 0.50 mg/mL and 0.125 mg/mL, respectively. Levels of IL-1ra, IL-6, IL-8, IL-17A, bFGF, MCP-1 and VEGF-A in dark culture with aflibercept or ranibizumab were more than 10 pg/mL.